Monalizumab | Innate Pharma

Preliminary data suggest promising anti-tumor activity of the combination of monalizumab and cetuximab in patients with platinum pretreated SCCHN

April 17, 2018

8 partial responses (PR) among 26 patients evaluable for efficacy – predefined number of responses needed to declare the trial result positive has been reached The combination was well tolerated...

New preclinical data further support ongoing programs and highlight next generation of immunotherapies

April 17, 2018

Next generation of immunotherapies presented by Chief Scientific Officer Eric Vivier in a meet-the-expert session at AACR 2018 New preclinical data further support ongoing clinical trials with...

Partner MedImmune expands colorectal cancer patient cohort in ongoing Phase I trial evaluating monalizumab in combination with Imfinzi® (durvalumab)

March 23, 2018

Additional expansion cohorts to explore the safety and efficacy of monalizumab in combination with durvalumab and standard of care in patients with 1 st - and 2 nd line, metastatic colorectal cancer...

Innate Pharma to present broad and innovative portfolio in immuno-oncology at AACR 2018

March 15, 2018

First clinical activity data of the combination of monalizumab and cetuximab New preclinical data further supporting the rationale of Innate’s first- or best-in-class antibodies Eric Vivier, Chief...

Innate Pharma Hosts R&D Day Today in London

March 8, 2018

Innate Pharma presents a clinical update on its broad and diverse development portfolio of first- or best-in-class antibodies in immuno-oncology Update on the development program with AstraZeneca on...

ICI conference 2017: new preclinical data further strengthen the rationale of IPH5401 and monalizumab for cancer treatments and in combination with anti-PD-1/PD-L1

September 11, 2017

IPH5401, an anti-C5aR antibody, potentially reverses tumor immuno-suppressive microenvironment and overcomes tumor resistance; preclinical data suggest that combined C5aR and PD-1 blockade...

Clinical and preclinical data on monalizumab to be presented at AACR annual meeting 2017

March 2, 2017

Reinforcing safety profile of monalizumab and rationale for broad ability to combine with other anticancer agents Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces...

Innate Pharma investor conference call on November 14, 2016 to discuss recent new clinical data

November 10, 2016

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that the Company will host a conference call for institutional investors and sell-side analysts to discuss recent...

First clinical data for monalizumab as a single agent in cancer patients show favorable safety profile

November 30, 2016

Data from the dose-ranging part of a Phase I/II trial of monalizumab in 18 patients with advanced gynecologic malignancies; Monalizumab had no dose-limiting toxicities, highest dose level chosen for...

Publications & Presentations

We are proud to contribute to the scientific advancements on innate immunity and NK cells. Since our founding in 1999, our researchers have been published in several high impact factor journals, highlighting our expertise in NK cell modulation and commitment to the highest quality science.

Read more about Publications & Presentations

Subscribe to Monalizumab

Company
Science
Products
- Pipeline overview
- ------------------
- Lacutamab
- IPH4502
- Monalizumab
- Other Clinical Stage Assets
  - IPH6501
  - IPH6101
  - IPH6401
  - IPH5201
  - IPH5301
Partnering
Investors
Media
Careers